Real-world Effectiveness of Molnupiravir and Nirmatrelvir/Ritonavir as Treatments for COVID-19 in Patients at High Risk
2023; Oxford University Press; Volume: 228; Issue: 12 Linguagem: Inglês
10.1093/infdis/jiad324
ISSN1537-6613
AutoresDimitrios Paraskevis, Maria Gkova, Kassiani Μellou, Gerasimos Gerolymatos, Naya Psalida, Kassiani Gkolfinopoulou, Evangelia Georgia Kostaki, Stelios Loukides, Αnastasia Kotanidou, Athanasios Skoutelis, Eleftherios Thiraios, Georgios Saroglou, Dimitrios C. Zografopoulos, Dimitrios Filippou, Elías Mossialos, Theoklis E. Zaoutis, Mina Gaga, Sotirios Tsiodras, Anastasia Antoniadou,
Tópico(s)Respiratory viral infections research
ResumoUsing a retrospective cohort study design, we aimed to evaluate the effectiveness of molnupiravir and nirmatrelvir/ritonavir in patients with SARS-CoV-2 who were highly vulnerable.
Referência(s)